FDA Issues Final Guidance on Clinical Investigations of Psychedelic Drugs
July 14, 2026
July 14, 2026
WASHINGTON, July 14 (TNSFR) -- The Department of Health and Human Services Food and Drug Administration has issued final guidance outlining recommendations for clinical investigations of psychedelic drugs treating medical and psychiatric conditions.
The guidance, titled Psychedelic Drugs: Considerations for Clinical Investigations, provides recommendations for sponsors developing psychedelic drugs to treat medical conditions, including psychiatric and substance use disorders. It add . . .
The guidance, titled Psychedelic Drugs: Considerations for Clinical Investigations, provides recommendations for sponsors developing psychedelic drugs to treat medical conditions, including psychiatric and substance use disorders. It add . . .